Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study-Reference-Cited by-同舟云学术

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Published:2018 Issue: Volume:11 Page:33
ISSN:1939-4551
Container-title:World Allergy Organization Journal
language:en
Short-container-title:World Allergy Organization Journal

Author:

Canonica Giorgio Walter,Rottoli Paola,Bucca Caterina,Zappa Maria Cristina,Michetti Giovanni,Macciocchi Bruno,Caruso Cristiano,Santus Pierachille,Bartezaghi Marta,Rigoni Laura

Funder

Novartis Farma SpA

Publisher

Elsevier BV

Subject

Immunology and Allergy,Immunology,Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40413-018-0214-3.pdf

Reference44 articles.

1. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice;Reddel;Am J Respir Crit Care Med,2009

2. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010;de Marco;Eur Respir J,2012

3. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma;Pereira Barbosa;Rev Port Pneumol (2006),2015

4. Severe asthma and allergy: mechanisms, diagnostics and treatment;Hedlin;J Intern Med,2012

5. Severe asthma and quality of life;Hossny;World Allergy Organ J,2017

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma;Frontiers in Allergy;2024-05-15

2. Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey;ERJ Open Research;2023-10-19

3. Asthma Phenotypes in the Era of Personalized Medicine;Journal of Clinical Medicine;2023-09-26

4. Oral Corticosteroid Reduction Between Biologics Initiated and Non-Initiated Patients with Severe Asthma;Journal of Asthma and Allergy;2023-08

5. The "real-world" effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study;Advances in Dermatology and Allergology;2023